Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Objectives: The survival and neurological prognosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome have been substantially improved by peripheral blood stem cell transplantation and immunomodulating agents since the 2000s. However, some pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoki Suichi, Sonoko Misawa, Kazumoto Shibuya, Marie Morooka, Moeko Ogushi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Emiko Sakaida, Satoshi Kuwabara
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Hematology
Subjects:
POEMS syndrome
multiple myeloma
monoclonal antibody
immunotherapy
immunomodulatory drug
proteasome inhibitor
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2025.2519896
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2025.2519896

Similar Items